首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1566162

大腸直腸癌治療藥物市場規模、佔有率、成長分析、按藥物類別、按癌症類型、按分銷管道、按地區 - 行業預測，2024-2031 年

Colorectal Cancer Therapeutics Market Size, Share, Growth Analysis, By Drug Class, By Cancer Type, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球大腸直腸癌治療市場規模預計為116億美元，從2023年的121.7億美元成長到2031年的178.4億美元，預測期（2024-2031年）預計複合年成長率為4.9%。

全球大腸直腸癌治療市場的發生率正在驚人地增加，這主要是由於久坐的生活方式、不健康的飲食選擇和人口老化所致。先進診斷和篩檢技術的引入促進了早期發現並實現了及時的治療性介入。此外，癌症治療領域的技術創新，例如標靶治療、免疫療法和聯合治療，可以提高治療效果並改善患者的治療結果，同時最大限度地減少副作用，也大大推動了市場的發展。然而，情況並非沒有挑戰。先進癌症治療的高昂費用給醫療保健系統帶來了沉重負擔，並可能導致各地區的醫療服務不平等。此外，抗藥性的出現使長期治療效果變得複雜，並成為患者實現長期緩解的主要障礙。監管障礙和複雜的報銷系統也構成了障礙，嚴格的醫藥品認證過程和不同的報銷政策可能會限制獲得先進治療的機會。儘管存在這些障礙，美國結直腸癌藥物市場仍將持續成長，預計在接下來的預測期內將實現穩定的年複合成長率（CAGR），這表明對對抗結直腸癌的創新解決方案的持續需求。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Amgen, Inc.（US）
Bayer AG（Germany）
Bristol-Myers Squibb Company（US）
Lilly（US）
Merck & Co., Inc.（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Sanofi（France）
Pfizer Inc.（US）
Novartis AG（Switzerland）
Regeneron Pharmaceuticals, Inc.（US）
AstraZeneca PLC（UK）
Gilead Sciences, Inc.（US）
Takeda Pharmaceutical Company Limited（Japan）
Ipsen Pharma（France）
Sumitomo Pharma Co., Ltd.（Japan）
Exelixis, Inc.（US）
BeiGene, Ltd.（China）
Oncolytics Biotech Inc.（Canada）
NantKwest, Inc.（US）
Eisai Co., Ltd.（Japan）
Incyte Corporation（US）
MacroGenics, Inc.（US）
Halozyme Therapeutics, Inc.（US）

簡介目錄

Product Code: SQMIG35A2691

Global Colorectal Cancer Therapeutics Market size was valued at USD 11.6 billion in 2022 and is poised to grow from USD 12.17 billion in 2023 to USD 17.84 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031).

The global colorectal cancer therapeutics market is experiencing robust growth driven by an alarming rise in the incidence of the disease, largely due to sedentary lifestyles, unhealthy dietary choices, and an increasingly aging population. The implementation of advanced diagnostic and screening techniques has facilitated early detection, enabling timely therapeutic interventions. Additionally, the market is significantly bolstered by innovations in cancer treatment, including targeted therapies, immunotherapies, and combination approaches that enhance treatment efficacy and improve patient outcomes while minimizing side effects. However, the landscape is not without challenges; the high costs associated with advanced cancer therapies present a substantial burden on healthcare systems, leading to potential inequities in access across different regions. Furthermore, the emergence of drug resistance complicates treatment efficacy over time, posing significant hurdles in achieving long-term remission for patients. Regulatory obstacles and intricate reimbursement systems also pose barriers, as stringent drug approval processes and variable reimbursement policies can restrict the accessibility of advanced therapies. Despite these hurdles, the US colorectal cancer therapeutics market is poised for sustainable growth, anticipated to achieve a steady compound annual growth rate (CAGR) in the upcoming forecast period, signaling a continued demand for innovative solutions in the fight against colorectal cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Colorectal Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Colorectal Cancer Therapeutics Market Segmental Analysis

Global Colorectal Cancer Therapeutics Market is segmented by Drug Class, Cancer Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Chemotherapy, Immunotherapy, and Others. Based on Cancer Type, the market is segmented into Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is significantly driven by a surge in awareness campaigns and comprehensive screening programs aimed at fostering early detection and diagnosis of colorectal cancer. As public health initiatives emphasize the importance of timely intervention, patients are increasingly accessing screenings that facilitate early identification of cancer, leading to improved treatment outcomes. This heightened awareness not only empowers individuals to seek appropriate medical care but also elevates the demand for innovative and effective therapeutics, as healthcare providers focus on optimizing treatment strategies for patients diagnosed at earlier stages of the disease. Consequently, this growing emphasis on early detection is a critical market driver.

Restraints in the Global Colorectal Cancer Therapeutics Market

A significant market restraint for the global colorectal cancer therapeutics market is the phenomenon of drug resistance that colorectal cancer cells can develop over time. This resistance diminishes the effectiveness of existing treatments, resulting in treatment failures and disease progression, which ultimately hampers patient survival rates. The challenge of overcoming this resistance complicates treatment protocols and necessitates the continuous development of new therapies, contributing to increased research and development costs. As a result, healthcare providers and pharmaceutical companies may face reduced treatment options and higher financial burdens, which can limit market growth and patient access to effective colorectal cancer therapeutics.

Market Trends of the Global Colorectal Cancer Therapeutics Market

The Global Colorectal Cancer Therapeutics market is witnessing a notable trend towards the rising popularity of combination therapies. These innovative treatment approaches, which integrate chemotherapy, targeted therapy, and immunotherapy, are being increasingly explored for their ability to enhance therapeutic efficacy. By leveraging the synergistic effects of multiple modalities, combination therapies can significantly improve response rates, effectively tackle drug resistance, and ultimately prolong survival rates among colorectal cancer patients. This trend reflects a shift in treatment paradigms, as healthcare providers and researchers aim for more personalized, effective solutions in managing colorectal cancer, positioning combination therapies as a cornerstone in future therapeutic strategies.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Colorectal Cancer Therapeutics Market by Drug Class

Market Overview
Chemotherapy
Immunotherapy
Others

Colorectal Cancer Therapeutics Market by Cancer Type

Market Overview
Colorectal Adenocarcinoma
Gastrointestinal Carcinoid Tumors
Others

Colorectal Cancer Therapeutics Market byDistribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Colorectal Cancer Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Amgen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeiGene, Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncolytics Biotech Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MacroGenics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Halozyme Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments